FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL |
|--------------|
|--------------|

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

|  |              |  |   |             | or se  | CUON  | 30(fi) of the fi                        | ivesime          | ni Coi  | прапу Аст          | JI 1940                  | J   |   |   |  |   |  |
|--|--------------|--|---|-------------|--|---|---|------------------|---|--------------------|--------------------------|---|---|---|--|---|--|
| BIOGEN IDEC INC  |              |  |   | TAF         | 2. Issuer Name and Ticker or Trading Symbol TARGETED GENETICS CORP /WA/ [ TGEN ] |   |   |                  |   |                    |                          |   |   | Relationship of Reporting Person(s) to Issuer (Check all applicable)      Director X 10% Owner      Officer (give title Other (specify) |  |   |  |
| (Last) (First) (Middle) 14 CAMBRIDGE CENTER  |              |  | 3. Date of Earliest Transaction (Month/Day/Year) 08/08/2005 |             |  |   |   |                  |   |                    |                          |   | below) below)   |   |  |   |  |
| (Street)   | IDGE M       | A  | 02142   |             | 4. If A  | mend  | lment, Date o                           | f Origina        | l Filed   | d (Month/Da        | ıy/Yeaı                  | r)  | 6. Ind<br>Line)   | Forn  | n filed by One<br>n filed by Mor                                   | Filing (Check A<br>Reporting Pers<br>e than One Rep               | on   |
| (City)   | (St          | ate)                                     | (Zip)   |             |  |   |   |                  |   |                    |                          |   |   | Pers  | son  |   |  |
|  |              | Tab                                      | le I - No   | n-Deriva    | ative S  | Secu  | ırities Acc                             | uired            | , Dis   | posed o            | f, or                    | Bene                                      | ficially  | Owne  | ed   |   |  |
| 1. Title of Security (Instr. 3)  |              |  | 2. Transaction<br>Date<br>(Month/Day/Year)                  |             | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year)                      |   | 3.<br>Transaction<br>Code (Instr.<br>8) |                  | 4. Securities Acquired (A)<br>Disposed Of (D) (Instr. 3, 4  |                    |                          |   | and 5) Securities Beneficially Owned Following Reported   |   | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4)  | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |  |
|  |              |  |   |             |  |   |   | Code             | v   | Amount             | (A<br>(D                 | ) or<br>)                                 | Price   |   | action(s)<br>3 and 4)  |   |  |
| Common   | Stock, \$0.0 | 1 Par Value                              |   | 08/08/      | 2005   |   |   | S                |   | 8,443              |                          | D   | \$0.76  | 11,   | 760,305  | I   | by<br>Biogen<br>Idec MA<br>Inc. <sup>(1)</sup> |
| Common   | Stock, \$0.0 | 1 Par Value                              |   | 08/08/      | 2005   |   |   | S                |   | 2,310              |                          | D :                                       | \$0.761   | 11,   | 757,995  | I   | by<br>Biogen<br>Idec MA<br>Inc. <sup>(1)</sup> |
| Common   | Stock, \$0.0 | 1 Par Value                              |   | 08/08/      | 2005   |   |   | S                |   | 2,500              |                          | D   | \$0.77  | 11,   | 755,495  | I   | by<br>Biogen<br>Idec MA<br>Inc. <sup>(1)</sup> |
| Common   | Stock, \$0.0 | 1 Par Value                              |   | 08/09/      | 2005   |   |   | S                |   | 2,000              |                          | D   | \$0.75  | 11,   | 753,495  | I   | by<br>Biogen<br>Idec MA<br>Inc. <sup>(1)</sup> |
| Common   | Stock, \$0.0 | 1 Par Value                              |   | 08/09/      | 2005   |   |   | S                |   | 3,000              |                          | D S                                       | \$0.7511  | 11,   | 750,495  | I   | by<br>Biogen<br>Idec MA<br>Inc. <sup>(1)</sup> |
| Common   | Stock, \$0.0 | 1 Par Value                              |   | 08/09/      | 2005   |   |   | S                |   | 7,200              |                          | D   | \$0.76  | 11,   | 743,295  | I   | by<br>Biogen<br>Idec MA<br>Inc. <sup>(1)</sup> |
|  |              | Т  |   |             |  |   | ties Acqui                              |                  |   |                    |                          |   |   | wned  |  |   |  |
| 1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  (Instr. 3)  3. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) |              | ned 4.<br>n Date, Transacti<br>Code (Ins |   | ion<br>str. | 5. Number of   | 6. Date Exer<br>Expiration D<br>(Month/Day) |   | sable and        | 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative<br>Security (Instr. 3<br>and 4) |                    | 8. I<br>De<br>Se<br>(In: | Price of<br>rivative<br>curity<br>str. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction<br>(Instr. 4) | Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4)   | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |   |  |
|  |              |  |   |             | Code V   | ,   | (A) (D)                                 | Date<br>Exercisa |   | Expiration<br>Date | Title                    | Amo<br>or<br>Num<br>of<br>Share           | ber   |   |  |   |  |

1. Name and Address of Reporting Person\*

**BIOGEN IDEC INC** 

(First)

(Middle)

14 CAMBRIDGE CENTER

| (Street) CAMBRIDGE  | MA             | 02142    |  |  |  |  |  |  |
|---|----------------|----------|--|--|--|--|--|--|
| (City)  | (State)        | (Zip)    |  |  |  |  |  |  |
| 1. Name and Address of Reporting Person* BIOGEN IDEC MA INC |                |          |  |  |  |  |  |  |
| (Last) 14 CAMBRIDGE   | (First) CENTER | (Middle) |  |  |  |  |  |  |
| (Street) CAMBRIDGE  | MA             | 02142    |  |  |  |  |  |  |
| (City)  | (State)        | (Zip)    |  |  |  |  |  |  |

## **Explanation of Responses:**

1. Shares are owned indirectly by Biogen Idec Inc. and directly by its wholly-owned subsidiary Biogen Idec MA Inc., fka Biogen, Inc.

## Remarks:

See Joint Filer information below.

Raymond G. Arner, Acting<br/>General Counsel08/10/2005Michael F. Phelps, Treasurer<br/>\*\* Signature of Reporting Person08/10/2005

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.